WordNet

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.

Pasquini MC1, Zhang MJ2, Medeiros BC3, Armand P4, Hu ZH5, Nishihori T6, Aljurf MD7, Akpek G8, Cahn JY9, Cairo MS10, Cerny J11, Copelan EA12, Deol A13, Freytes CO14, Gale RP15, Ganguly S16, George B17, Gupta V18, Hale GA19, Kamble RT20, Klumpp TR21, Lazarus HM22, Luger SM23, Liesveld JL24, Litzow MR25, Marks DI26, Martino R27, Norkin M28, Olsson RF29, Oran B30, Pawarode A31, Pulsipher MA32, Ramanathan M11, Reshef R23, Saad AA33, Saber W5, Savani BN34, Schouten HC35, Ringdén O36, Tallman MS37, Uy GL38, Wood WA Jr39, Wirk B40, Pérez WS5, Batiwalla M41, Weisdorf DJ42.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant.2016 Feb;22(2):248-57. doi: 10.1016/j.bbmt.2015.08.024. Epub 2015 Aug 29.
The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenet
PMID 26327629

Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome.

Trottier BJ1, Sachs Z1, DeFor TE1, Shune L1, Dolan M1, Weisdorf DJ1, Ustun C1, Warlick ED1.
Bone marrow transplantation.Bone Marrow Transplant.2016 Feb;51(2):199-204. doi: 10.1038/bmt.2015.274. Epub 2015 Nov 23.
Among patients with myelodysplastic syndrome (MDS) undergoing hematopoietic cell transplantation (HCT), the impact of residual pretransplant cytogenetically abnormal cells on outcomes remains uncertain. We analyzed HCT outcomes by time of transplant disease variables, including (1) blast percentage,
PMID 26595080

Gill H1, Leung AY1, Kwong YL1.
Future oncology (London, England).Future Oncol.2016 Feb 1. [Epub ahead of print]
Acute myeloid leukemia (AML) is molecularly heterogeneous. Formerly categorized cytogenetically and molecularly, AML may be classified by genomic and epigenomic analyses. These genetic lesions provide therapeutic targets. Genes targeted currently include mutated FLT3, NPM1 and KIT with drugs enterin
PMID 26828965